Nrf2 sensitizes prostate cancer cells to radiation via decreasing basal ROS levels

BioFactors

Volumn 41, Issue 1, 2015, Pages 52-57

  Liu, Min ^a   Yao, Xu Dong ^a   Li, Wei ^a   Geng, Jiang ^a,b   Yan, Yang ^a   Che, Jian Ping ^a   Xu, Yun Fei ^a   Zheng, Jun Hua ^a  

^a TONGJI UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Nrf2; Oxidative stress; Prostate cancer; Sulforaphane

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; LENTIVIRUS VECTOR; REACTIVE OXYGEN METABOLITE; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2; 12-O-TETRADECANOYLPHORBOL-1,3-ACETATE; ANDROGEN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; ISOTHIOCYANIC ACID DERIVATIVE; NFE2L2 PROTEIN, HUMAN; NFE2L2 PROTEIN, MOUSE; PHORBOL 13 ACETATE 12 MYRISTATE; SULFORAFAN; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CASTRATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; UPREGULATION; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DEFICIENCY; GAMMA RADIATION; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; THERAPEUTIC USE; TRANSGENIC MOUSE; TUMOR CELL LINE;

MUS;

ADENOCARCINOMA; ANDROGEN RECEPTOR ANTAGONISTS; ANDROGENS; ANIMALS; ANTICARCINOGENIC AGENTS; CASTRATION; CELL LINE, TUMOR; GAMMA RAYS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOTHIOCYANATES; MALE; MICE; MICE, TRANSGENIC; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TESTOSTERONE; TETRADECANOYLPHORBOL ACETATE;

EID: 84923372424     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.1200     Document Type: Article

References (23)

1. Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., and Samuels, A., et al. (2004) American Cancer Society. Cancer statistics, 2004. CA Cancer J. Clin. 54, 8-29.
2. Welz, S., Nyazi, M., Belka, C., and Ganswindt, U. (2008) Surgery vs. radiotherapy in localized prostate cancer. Which is best. Radiat. Oncol. 7, 3-23.
3. Nichol, A., Chung, P., Lockwood, G., Rosewall, T., Divanbiegi, L., et al. (2005) A phase II study of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy. Radiother. Oncol. 76, 11-17.
4. Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360, 103-106.
5. Sharifi, N., Gulley, J. L., and Dahut, W. L. (2005) Androgen deprivation therapy for prostate cancer. JAMA 294, 238-244.
6. Shiota, M., Song, Y., Takeuchi, A., Yokomizo, A., Kashiwagi, E., et al. (2012) Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer. J Urol. 187, 707-714.
7. Chen, Y., Clegg, N. J., and Scher, H. I. (2009) Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol. 10, 981-991.
8. Piao, M. S., Park, J. J., Choi, J. Y., Lee, D. H., Yun, S. J., et al. (2012) Nrf2-dependent and Nrf2-independent induction of phase 2 detoxifying and antioxidant enzymes during keratinocyte differentiation. Arch. Dermatol. Res. 304, 387-395.
9. Tanigawa. S., Lee, C. H., Lin, C. S., Ku, C. C., Hasegawa, H., et al. (2013) Jun dimerization protein 2 is a critical component of the Nrf2/MafK complex regulating the response to ROS homeostasis. Cell Death Dis. 4, e921.
10. Bromfield, G. P., Meng, A., Warde, P., and Bristow, R. G. (2003) Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill. Prostate Cancer Prostatic Dis. 6, 73-85.
11. Pinthus, J. H., Bryskin, I., Trachtenberg, J., Lu, J. P., Singh, G., et al. (2007) Androgen induces adaptation to oxidative stress in prostate cancer: implications for treatment with radiation therapy. Neoplasia 9, 68-80.
12. Shen, B., Wang, W., Ding, L., Sao, Y., and Huang, Y., et al. (2014) Nuclear factor erythroid 2-related factor 2 rescues the oxidative stress induced by di-N-butylphthalate in testicular Leydig cells. Hum. Exp. Toxicol. 10, pii: 0960327114530744.
13. Ripple, M. O., Henry, W. F., Rago, R. P., and Wilding, G. (1997) Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J. Natl. Cancer Inst. 89, 40-48.
14. Nichol, A. M., Warde, P., and Bristow, R. G. (2005) Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: clinical and translational issues. Cancer. 104, 891-905.
15. Itoh, K., Tong, K. I., and Yamamoto, M. (2004) Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. Free Radic. Biol. Med. 36, 1208-1213.
16. Frohlich, D. A., McCabe, M. T., Arnold, R. S., and Day, M. L. (2008) The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis. Oncogene. 27, 4353-4362.
17. Barve, A., Khor, T. O., Nair, S., Reuhl, K., Suh, N., et al. (2009) Gamma-tocopherol-enriched mixed tocopherol diet inhibits prostate carcinogenesis in TRAMP mice. Int. J. Cancer. 124, 1693-1699.
18. Cheung, K. L. and Kong, A. N. (2010) Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention. AAPS J. 12, 87-97.
19. Keum, Y. S., Jeong, W. S., and Kong, A. N. (2004) Chemoprevention by isothiocyanates and their underlying molecular signaling mechanisms. Mutat. Res. 555, 191-202.
20. Myzak, M. C. and Dashwood, R. H. (2006) Histone deacetylases as targets for dietary cancer preventive agents: lessons learned with butyrate, diallyl disulfide, and sulforaphane. Curr. Drug Targets. 7, 443-452.
21. Myzak, M. C. and Dashwood, R. H. (2006) Histone deacetylases as targets for dietary cancer preventive agents: lessons learned with butyrate, diallyl disulfide, and sulforaphane. Curr. Drug Targets. 7, 443-452.
22. Singh, S. V., Warin, R., Xiao, D., Powolny, A. A., Stan, S. D., et al. (2009) Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells. Cancer Res. 69, 2117-2125.
23. Keum, Y. S., Khor, T. O., Lin, W., Shen, G., Kwon, K. H., et al. (2009) Pharmacokinetics and pharmacodynamics of broccoli sprouts on the suppression of prostate cancer in transgenic adenocarcinoma of mouse prostate (TRAMP) mice: implication of induction of Nrf2, HO-1 and apoptosis and the suppression of Akt-dependent kinase pathway. Pharm Res. 26, 2324-2331.